Journal of Medicinal Chemistry · 2013 · 91 citations · 49 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryHemostasisMolecular PharmacologyAnticoagulant TherapyAnticoagulation TherapyEnzyme InhibitionHemostatic AgentsAllosteric DrugsAnticoagulant MechanismsAnticoagulant PharmacologyEnzymesFocused Library SynthesisHydrolysisPharmacological PotencyPlasma Anticoagulant Activity
Inhibition of factor XIa (FXIa) is a novel paradigm for developing anticoagulants without major bleeding consequences. We present the discovery of sulfated pentagalloylglucoside (6) as a highly selective inhibitor of human FXIa. Biochemical screening of a focused library led to the identification of 6, a sulfated aromatic mimetic of heparin. Inhibitor 6 displayed a potency of 551 nM against FXIa, which was at least 200-fold more selective than other relevant enzymes. It also prevented activation of factor IX and prolonged human plasma and whole blood clotting. Inhibitor 6 reduced V(MAX) of FXIa hydrolysis of chromogenic substrate without affecting the K(M), suggesting an allosteric mechanism. Competitive studies showed that 6 bound in the heparin-binding site of FXIa. No allosteric small molecule has been discovered to date that exhibits equivalent potency against FXIa. Inhibitor 6 is expected to open up a major route to allosteric FXIa anticoagulants with clinical relevance.
49
Pharmacology and Management of the Vitamin K Antagonists
Jack Ansell, Jack Hirsh, Elaine M. Hylek et al. · CHEST Journal · 2008 · 2.1K citations
Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy
Shannon M. Bates, Ian A. Greer, Ingrid Pabinger et al. · CHEST Journal · 2008 · 798 citations
Medicine, Hematology, Obstetrics +14
Plant polyphenols; Vegetable tannins revisited
International Journal of Biochemistry · 1990 · 557 citations
Agriculture, Botany, Plant Sciences +13